# Analyzing and utilizing NIH award data

## Perry Kirkham, Ph.D.

Office of the Vice President for Research

E-mail: pkirkham@purdue.edu

Phone: 63645



# What decisions can be informed through the use of NIH data?

Selection of home IC Selection of study section Selection of program officer Preparing for future proposals

## Institute and Center (IC) abbreviations

AA	NIH National Institute on Alcohol Abuse and Alcoholism (NIAAA)
AG	NIH National Institute on Aging (NIA)
AI	NIH National Institute of Allergy and Infectious Diseases (NIAID)
AR	NIH National Institute of Arthritis and Musculoskeletal and Skin
	Diseases (NIAMS)
AT	NIH National Center for Complementary and Integrative Health
	(NCCIH)
CA	NIH National Cancer Institute (NCI)
DA	NIH National Institute on Drug Abuse (NIDA)
DC	NIH National Institute on Deafness and Other Communication
	Disorders (NIDCD)
DE	NIH National Institute of Dental & Craniofacial Research (NIDCR)
DK	NIH National Institute of Diabetes and Digestive and Kidney Disease
	(NIDDK)
EB	NIH National Institute of Biomedical Imaging and Bioengineering
	(NIBIB)
ES	NIH National Institute of Environmental Health Sciences (NIEHS)
FV	NIH National Eva Instituta (NFI)

## Institute and Center (IC) abbreviations

GM	NIH National Institute of General Medical Sciences (NIGMS)
HD	NIH Eunice Kennedy Shriver National Institute of Child Health and
	Human Development (NICHD)
HG	NIH National Human Genome Research Institute (NHGRI)
HL	NIH National Heart, Lung and Blood Institute (NHLBI)
LM	NIH National Library of Medicine (NLM)
MD	NIH National Institute on Minority Health and Health Disparities
	(NIMHD)
MH	NIH National Institute of Mental Health (NIMH)
NR	NIH National Institute of Nursing Research (NINR)
NS	NIH National Institute of Neurological Disorders and Stroke (NINDS)
RM	NIH Roadmap
RR	National Center for Research Resources (NCRR) (dissolved 12/2011)
TR	NIH National Center for Advancing translational Sciences (NCATS)
TW	NIH Fogarty International Center (FIC)

- R01 NIH Research Project Grant Program (R01)
  - •Used to support a discrete, specified, circumscribed research project
  - •NIH's most commonly used grant program
  - •No specific dollar limit unless specified in FOA
  - •Advance permission required for \$500K or more (direct costs) in any year
  - •Generally awarded for 3 -5 years
  - Utilized by all ICs
  - •See parent FOA: PA-16-160
  - R03 NIH Small Grant Program (R03):
    - •Provides limited funding for a short period of time to support a variety of types of projects, including: pilot or feasibility studies, collection of preliminary data, secondary analysis of existing data, small, self-contained research projects, development of new research technology, etc.
    - Limited to two years of funding
    - Direct costs generally up to \$50,000 per year
    - Not renewable
    - Utilized by more than half of the NIH ICs
    - •See parent FOA: PA-16-162

- NIH Exploratory/Developmental Research Grant Award (R21)
  - •Encourages new, exploratory and developmental research projects by providing support for the early stages of project development. Sometimes used for pilot and feasibility studies.
  - Limited to up to two years of funding
  - •Combined budget for direct costs for the two year project period usually may not exceed \$275,000.
  - No preliminary data is generally required
  - Most ICs utilize
  - •See parent FOA: PA-16-161

- R34 NIH Clinical Trial Planning Grant (R34) Program
  - •Designed to permit early peer review of the rationale for the proposed clinical trial and support development of essential elements of a clinical trial
  - •Usually project period of one year, sometimes up to 3
  - •Usually, allows for a budget of up to \$100,000 direct costs, sometimes up to \$450,000
  - •Used only by select ICs; no parent FOA


# What is your problem?





Search NI

NI





Search

HOME | ABOUT RePORT | FAQs | GLOSSARY |

**QUICK LINKS** RESEARCH **ORGANIZATIONS** WORKFORCE **FUNDING** REPORTS LINKS & DATA





### The RePORT Expenditures and Results Tool (RePORTER)

Search a repository of NIH-funded research projects and access publications and patents resulting from that funding.











FUNDING FACTS



SPENDING







#### Research Portfolio Online Reporting Tools (RePORT)

In addition to carrying out its scientific mission, the NIH exemplifies and promotes the highest level of public accountability. To that end, the Research Portfolio Online Reporting Tools provides access to reports, data, and analyses of NIH research activities, including information on NIH expenditures and the results of NIH supported research.

#### Spotlight

NIH Categorical Spending (RCDC) for FY2017 now available, highlighting the annual support level for





	FY 2017	FY 2018	FY 2019
(Dollars in Thousands)	Final	Annualized CR	President's Budget
NCI	\$5,659,955	\$5,650,693	\$5,626,312
NHLBI	\$3,209,929	\$3,184,813	\$3,112,032
NIDCR	\$424,797	\$422,860	\$413,196
NIDDK <sup>1</sup>	\$2,009,504	\$2,007,892	\$1,965,434
NINDS	\$1,778,688	\$1,771,541	\$1,838,556
NIAID	\$4,905,718	\$4,873,317	\$4,761,948
NIGMS <sup>2</sup>	\$2,646,152	\$2,632,836	\$2,572,669
NICHD	\$1,376,608	\$1,370,921	\$1,339,592
NEI	\$731,212	\$727,643	\$711,015
NIEHS <sup>3</sup>	\$790,018	\$786,234	\$747,166
NIA	\$2,048,814	\$2,034,698	\$1,988,200
NIAMS	\$556,606	\$554,063	\$545,494
NIDCD	\$435,904	\$433,908	\$423,992
NIMH	\$1,604,658	\$1,591,052	\$1,612,192
NIDA	\$1,070,846	\$1,083,445	\$1,137,403
NIAAA	\$482,451	\$480,080	\$469,109
NINR	\$149,937	\$149,252	\$145,842
NHGRI	\$528,346	\$524,977	\$512,979
NIBIB	\$356,981	\$354,655	\$346,550
NIMHD	\$287,670	\$287,106	\$280,545
NCCIH	\$134,389	\$133,774	\$130,717
NCATS	\$704,330		\$685,087
FIC	\$71,852	\$71,723	\$70,084
NLM	\$406,604	\$404,743	\$395,493
B&F	\$128,567		\$200,000
OD	\$1,728,603	\$1,706,132	\$2,004,306

NIH Institutes	Activity Code	Number Reviewed	Number Awarded	Success Rate <sup>3</sup>	Total Funding⁴
NCI	R21	1,901	153	8.0%	\$30,515,060
NHLBI	R21	333	35	10.5%	\$5,483,504
NIDCR	R21	220	22	10.0%	\$4,973,237
NIDDK	R21	407	30	7.4%	\$6,810,635
NINDS	R21	1,344	188	14.0%	\$44,525,922
NIAID	R21	2,550	408	16.0%	\$92,462,775
NIGMS	R21	3	3	100.0%	\$549,332
NICHD	R21	1,194	152	12.7%	\$34,694,103
NEI	R21	323	49	15.2%	\$11,260,172
NIEHS	R21	336	37	11.0%	\$8,696,641
NIA	R21	865	186	21.5%	\$43,408,922
NIAMS	R21	570	79	13.9%	\$15,852,639
NIDCD	R21	266	56	21.1%	\$11,150,098
NIMH	R21	678	120	17.7%	\$27,124,729
NIDA	R21	539	109	20.2%	\$24,411,427
NIAAA	R21	275	46	16.7%	\$9,847,715
NINR	R21	253	10	4.0%	\$2,359,940
NHGRI	R21	83	14	16.9%	\$3,617,712
NIBIB	R21	860	73	8.5%	\$15,822,295
NCCIH	R21	64	4	6.3%	\$647,308
NIMHD	R21	139	18	12.9%	\$4,232,327
FIC	R21	158	13	8.2%	\$2,570,409
NLM	R21	46	6	13.0%	\$1,172,743
NCATS	R21	11	4	36.4%	\$927,852
OD ORIP-SEPA†	R21	75	11	14.7%	\$2,306,984

Tittps://grants.innigov/ranang/index.itm





#### Grants & Funding

NIH's Central Resource for Grants and Funding Information

Entire Site

eRA I an

HOME ABOUT GRANTS FUNDING POLICY & COMPLIANCE NEWS & EVENTS

Home » Funding

#### **Funding**

Grants (NIH Guide to Grants and Contracts)

Contracts

Research Training and Career Development &

Loan Repayment Programs @

Extramural Diversity Website 🗗

### **Funding**

NIH offers funding for many types of grants, contracts, and even programs that help repay loans for researchers. Learn about the programs, as well as about NIH's budget process, grant funding strategies, and policies, and more.



#### **Grants (NIH Guide to Grants and Contracts)**

The NIH Guide for Grants and Contracts is our official publication for NIH grant policies, guidelines and funding opportunities. We publish daily, and issue a table of contents weekly. Learn more about the NIH Guide and subscribe today!

#### **View all Parent Announcements**

(for unsolicited applications)

Search for funding opportunities and notices





#### **Contracts**

Interested in exploring opportunities at NIH for research and development contract funding? Learn the basics of how contracts differ from grants, how you can find solicitations and submit your proposal, how they are submitted and evaluated, and more.

procipinico.	040			
Notice of Clarification Regarding Letters of Support for PAR-17-025, "Aging Research Dissertation Awards to Increase Diversity (R36)"	NOT- AG-18- 037	NIA	Oct 29, 2018	N/A
Notice of Intent to Publish Parent Funding Opportunity Announcements for Basic Experimental Studies with Humans	NOT- OD-19- 024	NIH	Oct 26, 2018	N/A
Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01 Clinical Trial Not Allowed)	PAR-19- 039	NINDS	Oct 26, 2018	Sep 1!
Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01 Clinical Trial Optional)	PAR-19- 040	NINDS	Oct 26, 2018	Sep 15 2021
Early Screening for Autism Spectrum Disorder (R01 Clinical Trial Not Allowed)	RFA- MH-19- 120	NIMH	Oct 25, 2018	Feb 5, 2019
Early Screening for Autism Spectrum Disorder (R21 Clinical Trial Not Allowed)	RFA- MH-19- 121	NIMH	Oct 25, 2018	Feb 5, 2019
Emerging Global Leader Award (K43 Independent Clinical Trial Required)	PAR-19- 038	FIC	Oct 25, 2018	Nov 5, 2020
Changes in NIGMS Support of Integrated Predoctoral Dual-degree M.DPh.D. Training through the Medical Scientist Training Program	NOT- GM-18- 047	NIGMS	Oct 25, 2018	N/A


### Part 1. Overview Information

Catalog of Fodoral Domostic Assistance (CEDA)

Participating Organization(s)	National Institutes of Health (NIH)
Components of Participating Organizations	National Institute of Neurological Disorders and Stroke (NINDS)
	National Eye Institute (NEI)
	National Institute of Arthritis and Musculoskeletal and Skin Disease
	National Institute on Drug Abuse (NIDA)
	National Institute of Environmental Health Sciences (NIEHS)
Funding Opportunity Title	Countermeasures Against Chemi Identification of Therapeutic Lead Trial Not Allowed)
Activity Code	U01 Research Project – Cooperative Agreements
Announcement Type	Reissue of PAR-16-330
Related Notices	None
Funding Opportunity Announcement (FOA) Number	PAR-19-039
Companion Funding Opportunity	PAR-18-721, R21 Exploratory/Developmental Grant
	PAR-18-657, U54 Specialized Center - Cooperative Agreements
	PAR-19-040, U01 Research Project – Cooperative Agreements
	PAR-19-040 - U01 Research Project – Cooperative Agreements
Number of Applications	See Section III. 3. Additional Information on Eligibility.

02 052: 02 067: 02 046: 02 112: 02 270

#### PROJECT DETAILS



ClinicalTrials.gov ID: Format: NCT00000419

5 entry maximum separated by commas.

There were 7 results matching your search criteria.

Click on the column header to sort the results

	T Act	Project Year Sub	# Project Title	Contact PI/ Project Leader	Organization	FY	Admin IC	Fund
	<u>5 U01</u>	ES028182 02	TARGETING CARDIOPULMONARY CALPAINS TO MITIGATE TOXICITY OF HALOGEN GASES.	AHMAD, SHAMA et al.	UNIVERSITY OF ALABAMA AT BIRMINGHAM	2018	NIEHS	01
	1 <u>U01</u> <u>N</u>	NS102135 01A1	ANTIGLUTAMATERGIC THERAPY TO PROTECT THE IMMATURE BRAIN AGAINST NERVE AGENTS	BRAGA, MARIA F.	HENRY M. JACKSON FDN FOR THE ADV MIL/MED	2018	NINDS	OI
<b></b>	<u>1 U01</u>	NS107127 01	IDENTIFICATION OF NOVEL BRAIN- PENETRATING PHENOXYALKYL PYRIDINIUM OXIME COUNTERMEASURES	CHAMBERS, JANICE ELAINE	MISSISSIPPI STATE UNIVERSITY	2018	NINDS	OI
	<u>5 U01</u>	NS102131 02	NEUROSTEROIDS AS A STANDARD MEDICAL COUNTERMEASURE FOR OP POISONING	GEE, KELVIN W. et al.	UNIVERSITY OF CALIFORNIA-IRVINE	2018	NINDS	O
	<u>5 U01</u>	ES028187 02	TIE2 ACTIVATION FOR THE TREATMENT OF CHEMICAL-INDUCED ACUTE LUNG INJURY	KONTOS, CHRISTOPHER D	DUKE UNIVERSITY	2018	NIEHS	OI
	1 <u>U01</u> <u>N</u>	NS109793 01A1	CYANIDE/AZIDE DETOXIFICATION BY NEW COBALT COMPLEXES AND NO DONORS	PETERSON, JAMES et al.	UNIVERSITY OF PITTSBURGH AT PITTSBURGH	2018	NINDS	OI
	1 <u>U01</u> <u>N</u>	NS102101 01A1	ANTICHOLINERGIC AND ANTIEPILEPTIC THERAPIES FOR CHLORINE TOXICITY	VERESS, LIVIA AGNES	UNIVERSITY OF COLORADO DENVER	2018	NINDS	OI

Home > Reporter > Project information \*\*\* KEPOKTEK Logiii | Register | RefortER Mariual Project Information Back to Query Form Back to Search Results Prin 5U01FS028182-02 Project 1 of 7 PI PROFILE LINKS

RESULTS HISTORY SUBPROJECTS SIMILAR PROJECTS NEARBY PROJECTS BETA DESCRIPTION **DETAILS** LINKS 🗹 NEWS AND MORE ☑ Contact PI / Project Leader: Project Number: 5U01ES028182-02 AHMAD, SHAMA

TARGETING CARDIOPULMONARY CALPAINS TO MITIGATE TOXICITY OF Awardee Organization: UNIVERSITY OF ALABAMA AT BIRMINGHAM Title: HALOGEN GASES

A No P Profile Exists Contact PI / Project Leader Information: 1 **Program Official Information:** Other PI Information: Name: AHMAD, SHAMA 💍 DELL'ITALIA, LOUIS J. 💍 Name: NADADUR, SRIKANTH

Email: Click to view PO email address Email: Click to view Contact PI / Project Leader

email address

Title: ASSOCIATE PROFESSOR

Department Type/ Organization Type: Congressional District: Organization:

Name: UNIVERSITY OF ALABAMA AT BIRMINGHAM State Code: AL ANESTHESIOLOGY

City: BIRMINGHAM Country: UNITED STATES (US) SCHOOLS OF MEDICINE District: 07

Other Information:

FOA: PAR-16-330 DUNS Number: 063690705 CFDA Code: 113

Project Start Date: 15-AUG-2017 Project End Date: 31-JUL-2020 Study Section: Special Emphasis Panel [ZRG1-MDCN-B (50)R] Budget Start Date: 1-AUG-2018 Budget End Date: 31-JUL-2019 Fiscal Year: 2018 Award Notice Date: 1-AUG-2018

Administering Institutes or Centers:

NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES

**Project Funding Information for 2018:** 

Total Funding: \$394,553	Direct Costs: \$2	275,000	Indirect Costs: \$119,553
Year	Funding IC	FY Total Cost by IC	
2018	OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH	\$394,553	

DESCRIPTION DETAILS RESULTS HISTORY SUBPROJECTS SIMILAR PROJECTS NEARBY PROJECTS BETA LINKS & NEWS AND MORE &

Project Number: 5U01ES028182-02 Contact PI / Project Leader: AHMAD, SHAMA

Title: TARGETING CARDIOPULMONARY CALPAINS TO MITIGATE TOXICITY OF Awardee Organization: UNIVERSITY OF ALABAMA AT BIRMINGHAM

HALOGEN GASES.

#### **Abstract Text:**


Accidental leaks from manufacturing plants are common and large groups of people may be exposed to high halogen (Cl2/Br2) concentrations. Use of halogen gases as chemical weapons is also on the rise. Victims of accidental bromine exposure experience respiratory distress, cardiac arrest and circulatory collapse. Studies evaluating acute and chronic sequelae of Br2 exposure are scant and treatment remains symptomatic as no effective countermeasures exist. Our studies have established that the heart is severely injured in animals that survive high dose halogen (Cl2/Br2) inhalation. The purpose of this application is to identify the biological mechanisms responsible for these events and develop appropriate countermeasures. Based on exciting preliminary data we propose that brominated reactants such as brominated lipids are produced in the lungs. Brominated reactants/lipids reach the heart along with oxygenated blood. These reactants inactivate important calcium pumps that regulate the heartbeats. Inactivity of calcium pumps causes calcium accumulation or "calcium overload" in the heart cells. Calcium overload is a serious problem and can lead to sudden cardiac death. Increased calcium also activates destructive proteins, the calpains that destroy cardiac ultrastructure. We therefore hypothesize that Br2 inhalation produces highly reactive intermediates that activate Ca2+ sensitive calpains leading to cytoskeletal and mitochondrial damage and myocardial dysfunction and that calpain inhibition will mitigate Br2-induced cardiopulmonary dysfunction and death. These hypotheses will be tested by completing the experiments outlined in the following specific aims. SA#1: Characterize cardiac injury and death induced by Br2 inhalation. SA#2: Test the hypothesis that Br2 and Br2 reactants activate cardiac calpains and cause cytoskeletal and mitochondrial damage. SA#3: Test whether calpain inhibitor based countermeasures mitigate acute and chronic effects caused by Br2 inhalation. The outcome from this project will identify an

#### **Public Health Relevance Statement:**

The proposed research is relevant to public health because new treatment strategies for halogen inhalation- induced toxicity are desperately needed. Halogen gases such as bromine are highly reactive, corrosive 'inhalational' threat agent that can spread both as liquid and as fumes. Inhalation of bromine causes extensive injury to the lungs and the heart. Our goals are to identify the biochemical and molecular mechanisms responsible for these injuries and develop effective countermeasures.


#### **Project Terms:**

Acute; Adult; Amines; Animals; Antidotes; base; Biochemical; Biological; Blood; Blood Circulation; Blood Gas Analysis; Bromine; Ca(2+)-Transporting ATPase; Calcium; Calpain; calpain inhibitor; Cardiac; Cardiac Death; Cardiac Myocytes; Cardiopulmonary; cardiopulmonary system; Cardiotoxicity; Cell Death; Cessation of life; Chemical Weapons; Chlorine; Chronic; Clinical; Coronary; Corrosives; Data; Development; Distress; Dose; Echocardiography; effective therapy; Electrocardiogram; Emergency Situation; Epithelial; Evaluation; Event; experience; experimental study; Exposure to; fatty aldehyde; Functional disorder; Gases; Goals; Halogens; Hazardous Substances; Heart; Heart Arrest; heart cell; Heart failure; heart function; Heart Injuries; hemodynamics; Homeostasis; Human; Impairment; improved; In Vitro; in vivo; Industrialization; Inhalation; injured; Injury; Ions; Knowledge; Lead; Left; Lipids; Liquid substance; Lung; Mitochondria; Molecular; Morbidity - disease rate; mortality; Myocardial dysfunction; Myocardium; Outcome; Peptide Hydrolases; Peptides; Physiological; Plants; Plasma; Preparation; prevent; primary outcome; Production; Proteins; Public Health; Pulse Oximetry; Pump; Rattus; Readiness; Research; respiratory; Respiratory distress; Reticulum; secondary outcome; Shock; sudden cardiac death; Surface; Telemetry; Testing; Therapeutic; time interval; Toxic effect; Treatment Efficacy; treatment strategy; vascular bed; Ventricular





# What awards have been made from a given study section?



# What ideas or fields are funded by the NIH in general and an institute in specific?

Council reports
Director's budget requests
RePORTER data
Program officer

<u>Center</u> and pick "Concepts, Potential Funding Opportunities" as a topic of interest.

DAIDS	DAIT	DMID	Trans-Divisional
September 2016	September 2016	September 2016	None
<u>June 2016</u>	June 2016	<u>June 2016</u>	<u>June 2016</u>
January 2016	January 2016	January 2016	None
September 2015	September 2015	September 2015	September 2015
<u>May 2015</u>	<u>May 2015</u>	<u>May 2015</u>	None
January 2015	January 2015	January 2015	None

# Concepts May Turn Into Initiatives

#### SUMMARY STATEMENT

( Privileged Communication )

Release Date: 06/15/2010

Eun-Chung Park 301-496-7453

epark@niaid.nih.gov

PROGRAM CONTACT:

Application Number: 1 R01 Al092571-01

**Principal Investigator** 

PARRISH, COLIN R. PHD

Applicant Organization: CORNELL UNIVERSITY ITHACA

Review Group: ZRG1 IDM-R (03)

Center for Scientific Review Special Emphasis Panel

**Member Conflict: Viruses** 

Meeting Date: 05/25/2010 RFA/PA: PA10-067

Council: OCT 2010 PCC: M34A

Requested Start: 12/01/2010

Project Title: Structural controls of functional receptor and antibody binding to viral capsids

SRG Action: Impact/Priority Score: 20 Percentile: 7 #

Human Subjects: 10-No human subjects involved

Animal Subjects: 30-Vertebrate animals involved - no SRG concerns noted

Project	Direct Costs	Estimated
Year	Requested	Total Cost
1	250,000	388,910
2	250,000	388,910
3	250,000	388,910
4	250,000	388,910
5	250,000	388,910
TOTAL	1,250,000	1,944,550

#### **CRITIQUE 1:**

Significance: 2 Investigator(s): 1 Innovation: 1 Approach: 2 Environment: 1

**Overall Impact:** This application is to investigate the structural and physical properties of biofilms using a wide range of novel techniques developed by the team and how these properties affect infections, antibiotic resistance, resistance to immune invasion and virulence. The proposed study is very novel in several aspects including novel techniques used, different properties to be studied, new insights into biofilm development, etc. This application has been improved substantially from the previous applications and the team has made several progresses with published records to support the current study. A few concerns still exist including coordination of the research activities, unclear description of budgets, inconsistence in description of research activities and justification of animal to be used.

#### 1. Significance:

#### Strengths

- It is novel to investigate the structural and physical properties of biofilms.
- Better understanding of such properties will likely lead to develop novel control strategies.

#### Weaknesses

#### 2. Investigator(s):

#### Strengths

All investigators have published extensively in the areas of proposed research.

#### Weaknesses

# Federal RePORTER http://federalreporter.nih.gov/





